Organizations & Partners
The Baillet Latour Fund, Belgium
The Baillet Latour Fund in Belgium supports projects and provides awards in four pillars: healthcare, education, heritage and sports. All approved projects have a Belgian dimension with international resonance. The fund supports, valorises and stimulates human excellence with attention for societal evolution.
In this context, the Fund provides seed financing to the BioPontis Alliance for Rare Diseases, in its mission to develop early-stage therapies for unmet medical needs in the field of rare diseases of the brain and nervous system. The seed financing of the Baillet Latour Fund will enable BioPontis to start its first development program, and is meant to encourage others to support BioPontis financially and otherwise .
UZ Leuven, Belgium
BioPontis Alliance for Rare Diseases is an international public charity that is dedicated to finding treatments for people with rare diseases that affect the nervous system. Their approach is collaborative with patients’ groups , researchers and clinicians at academic research institutions. Given the enormous need for therapies in rare diseases in general and in neurology in particular, we endorse this approach enthusiastically and our hospital departments will consider to support and collaborate with BioPontis. We encourage the cooperation of all who are involved in the development of treatments to change the life of rare disease patients worldwide who are today often overlooked in spite of scientific progress.
BioPontis Alliance for Rare Diseases is an international public charity dedicated to finding treatments for people with rare diseases affecting the nervous system and the brain. BioPontis’ unique approach is to bring together centers of excellence in life sciences research, such as VIB, with regulatory and industry experts, translational clinicians and disease experts from patients’ groups. This will create a synergistic effect and drive the translation of promising academic discovery research into therapeutic candidates. Given VIB’s track record in top-level science and technology transfer, the expertise of VIB scientists in rare neurological diseases and VIB’s mission to translate research into benefits for society, VIB strongly endorses the BioPontis Alliance for Rare Disease initiative. BioPontis Alliance and VIB look forward to collaborate on specific disease programs that are often neglected due to their rarity or complexity.
VIB is a non-profit research institute in life sciences. About 1,400 scientists conduct strategic basic research on the molecular mechanisms that are responsible for the functioning of the human body, plants, and microorganisms. The goal of the research is to extend the boundaries of our knowledge of life. Through its technology transfer activities, VIB translates research results into products for the benefit of consumers and patients and contributes to new economic activity. More information: www.vib.be
At the University of Antwerp we are really looking forward to cooperating with BioPontis Alliance and her partners, in the strategic partnership on rare diseases. BioPontis Alliance for Rare Diseases is a unique organization. Worldwide there are millions of rare disease patients who live with no hope of treatment today. BioPontis Alliance takes their fate to heart and goes any length in the development of therapies.
Our university will be involved in a project on Charcot-Marie-Tooth Disease (CMT). There are no therapies available for CMT patients today, although it affects 1/2500 worldwide. Dr Albena Jordanova and her team have a lot of experience in such research. They will enthusiastically dedicate themselves to battling this disease, firmly convinced to solve the mystery of CMT.
The University of Antwerp is a research university where pioneering, innovative research is conducted at an international level. Research and education are closely linked. Educational innovation is a constant focus, and special care is also taken to welcome and guide each of the 20,000 students spread across our nine faculties.
The University of Antwerp is not an island: we build bridges to secondary education, to industry and, by extension, to society as a whole. With over 5,000 members of staff, the University of Antwerp is one of the most important employers in Antwerp, Flanders’ largest city.
More information: www.uantwerp.be